Antifungal agents: spectrum of activity, pharmacology, and clinical indications

JE Nett, DR Andes - Infectious Disease Clinics, 2016 - id.theclinics.com
Continued advancement of medical science offers life-saving treatment options for a variety
of hematologic, oncologic, and rheumatologic conditions. Immunosuppression, a common …

Candida Infections, Causes, Targets, and Resistance Mechanisms: Traditional and Alternative Antifungal Agents

C Spampinato, D Leonardi - BioMed research international, 2013 - Wiley Online Library
The genus Candida includes about 200 different species, but only a few species are human
opportunistic pathogens and cause infections when the host becomes debilitated or …

Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America

TF Patterson, GR Thompson III… - Clinical infectious …, 2016 - academic.oup.com
It is important to realize that guidelines cannot always account for individual variation among
patients. They are not intended to supplant physician judgment with respect to particular …

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy

B Moriyama, AO Obeng, J Barbarino… - Clinical …, 2017 - Wiley Online Library
Voriconazole, a triazole antifungal agent, demonstrates wide interpatient variability in serum
concentrations, due in part to variant CYP2C19 alleles. Individuals who are CYP2C19 …

Tissue penetration of antifungal agents

T Felton, PF Troke, WW Hope - Clinical microbiology reviews, 2014 - Am Soc Microbiol
Understanding the tissue penetration of systemically administered antifungal agents is
critical for a proper appreciation of their antifungal efficacy in animals and humans. Both the …

Defining breakthrough invasive fungal infection–Position paper of the mycoses study group education and research consortium and the European Confederation of …

OA Cornely, M Hoenigl, C Lass‐Flörl, SCA Chen… - Mycoses, 2019 - Wiley Online Library
Breakthrough invasive fungal infections (IFI s) have emerged as a significant problem in
patients receiving systemic antifungals; however, consensus criteria for defining …

Polymorphism of human cytochrome P450 enzymes and its clinical impact

SF Zhou, JP Liu, B Chowbay - Drug metabolism reviews, 2009 - Taylor & Francis
Pharmacogenetics is the study of how interindividual variations in the DNA sequence of
specific genes affect drug response. This article highlights current pharmacogenetic …

Current concepts in antifungal pharmacology

RE Lewis - Mayo Clinic Proceedings, 2011 - Elsevier
The introduction of new antifungal agents (eg, echinocandins, second-generation triazoles)
in the past decade has transformed the management of invasive mycoses to the point that …

The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial

WB Park, NH Kim, KH Kim, SH Lee… - Clinical Infectious …, 2012 - academic.oup.com
Background. Blood levels of voriconazole, a first line therapy for invasive aspergillosis, may
correlate with adverse events and treatment response. However, no randomized controlled …

Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents

RJM Brüggemann, JWC Alffenaar… - Clinical Infectious …, 2009 - academic.oup.com
There are currently a number of licensed azole antifungal drugs; however; only 4 (namely,
fluconazole, itraconazole, posaconazole, and voriconazole) are used frequently in a clinical …